

# WHO Expert Committee on Biological Standardization

---

Fifty-ninth report



World Health  
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about four to six such reports, costs CHF 150.00/US\$ 180.00 (CHF 105.00/US\$ 126.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int); order on line: <http://www.who.int/bookorders>).

W H O T e c h n i c a l R e p o r t S e r i e s

# WHO Expert Committee on Biological Standardization

---

Fifty-ninth report

*This report contains the collective views of an international group of experts and  
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health  
Organization**

#### WHO Library Cataloguing-in-Publication Data

Fifty-ninth report/WHO Expert Committee on Biological Standardization.

(WHO technical report series ; no. 964)

1. Biological products - standards. 2. Vaccines - standards. 3. Reference standards.  
4. Guidelines. I. World Health Organization. II. WHO Expert Committee on Biological  
Standardization (2008: Geneva, Switzerland). III. Series.

ISBN 978 92 4 120964 6

(NLM classification: QW 800)

ISSN 0512-3054

#### ©World Health Organization 2012

All rights reserved. Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site ([http://www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

# Contents

|   |    |
|---|----|
| <b>Expert Committee on Biological Standardization</b>   | v  |
| <b>Introduction</b>   | 1  |
| <b>General</b>  | 3  |
| Strategic directions in biological standardization  | 3  |
| Vaccines and biological therapeutics: recent and planned activities<br>in biological standardization                                  | 4  |
| Blood products and related in vitro diagnostics: recent and planned activities<br>in biological standardization                       | 5  |
| Reports from the WHO International Laboratory and Collaborating Centres for<br>Biological Standards                                   | 6  |
| Scientific issues identified by users of WHO biological reference preparations  | 8  |
| Joint session with the Expert Committee on Specifications for<br>Pharmaceutical Preparations  | 8  |
| Quality control parameters and their relevance to WHO International Standards   | 10 |
| <b>International recommendations, guidelines, and other matters related<br/>to the manufacture and quality control of biologicals</b> | 13 |
| Recommendations for Yellow vaccine  | 13 |
| Abbreviated licencing pathways for certain biological therapeutic products  | 14 |
| Poliovirus vaccines   | 15 |
| Guidelines for Lot Release of Vaccines  | 16 |
| Priorities for work on new or revised recommendations or guidelines for vaccines  | 16 |
| Nomenclature for biological medicines: vaccine abbreviations  | 18 |
| Production, control and regulation of snake anti-venom immunoglobulins  | 18 |
| Selection of venoms and preclinical assessment of antivenom immunoglobulins   | 19 |
| Need for regulation of blood products in developing countries   | 20 |
| <b>International reference materials</b>  | 21 |
| <b>Antibiotics</b>  | 21 |
| Gramicidin, 2 <sup>nd</sup> International Standard  | 21 |
| <b>Antigens and related substances</b>  | 23 |
| Influenza H5N1 antibody (human), 1 <sup>st</sup> International Standard   | 23 |
| Human papillomavirus type 16 DNA, 1 <sup>st</sup> International Standard  | 23 |
| Human papillomavirus type 18 DNA, 1 <sup>st</sup> International Standard  | 23 |
| Rabies vaccine, 6 <sup>th</sup> International Standard  | 24 |
| Acellular Pertussis vaccine, 1 <sup>st</sup> International Standard for potency assay<br>by Modified Kendrick Test                    | 25 |
| Pertussis antiserum (human), 1 <sup>st</sup> International Standard   | 27 |
| <b>Blood products and related substances</b>  | 29 |
| Anti-hepatitis B surface antigen (anti-HBs) immunoglobulin, human,<br>2 <sup>nd</sup> International Standard                          | 29 |
| Blood coagulation factor IX, concentrate, 4 <sup>th</sup> International Standard  | 30 |
| Factor VIIa concentrate, 2 <sup>nd</sup> International Standard   | 31 |

|  |     |
|--|-----|
| Parvovirus B19 DNA, plasma, human, 2 <sup>nd</sup> International Standard  | 33  |
| Anti-A and anti-B antibodies in intravenous immunoglobulin, human,<br>WHO reference reagents   | 34  |
| Anti-hepatitis B core antigen (anti-HBc), plasma, human, 1 <sup>st</sup> International Standard  | 36  |
| Alpha-1-antitrypsin; assignment of a total protein and antigenic concentration<br>to the 1 <sup>st</sup> International Standard, and extension of its use to assign<br>potencies to recombinant products | 38  |
| <b>Cytokines, growth factors and endocrinological substances</b>   | 41  |
| Insulin-like growth factor (IGF-1), 1 <sup>st</sup> International Standard   | 41  |
| <b>Diagnostic reagents</b>   | 43  |
| Haemophilia A intron 22 inversion, 1 <sup>st</sup> reference panel for<br>molecular genetic diagnosis  | 43  |
| Fragile X syndrome, 1 <sup>st</sup> reference panel for molecular genetic diagnosis  | 44  |
| <b>Proposed new reference preparation projects</b>   | 47  |
| <b>Annex 1</b>   |     |
| Addendum to Requirements for yellow fever vaccine  | 49  |
| <b>Annex 2</b>   |     |
| Guidelines for the production, control and regulation of snake<br>antivenom immunoglobulins  | 57  |
| <b>Annex 3</b>   |     |
| Biological substances – International Standards and Reference Reagents   | 223 |
| <b>Annex 4</b>   |     |
| Recommendations and guidelines for biological substances used in medicine<br>and other documents   | 225 |

# Expert Committee on Biological Standardization

13 to 17 October 2008

## Members<sup>1</sup>

Dr W.G. van Aken, Amstelveen, the Netherlands

Dr D. Calam, Pewsey, Wiltshire, UK (*Rapporteur*)

Dr M.M. Farag Ahmed, Assistant Professor Clinical and Chemical Pathology Research Department, National Organisation for Drug Control and Research (NODCAR), Head of Biologicals & Vaccines, Agousa, Egypt

Dr J. Epstein, Director, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD, USA

Dr E. Griffiths, Associate Director General, Biologics and Genetic Therapies, Health Canada, Ottawa, Ontario, Canada

Mrs T. Jivapaisarnpong, Director, Division of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand (*Vice-chair*)

Dr H. Klein, National Institutes of Health, Warren G. Magnuson Clinical Center, Department of Transfusion Medicine, Bethesda, MD, USA

Dr J. Löwer, President, Paul Ehrlich Institut, Langen, Germany

Dr P. Minor, Head, Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Herts, UK (*Chairman*)

Dr P. Strengers, Medical Director, Division of Plasma Products, Sanquin, Amsterdam, the Netherlands

## Representatives from other organizations

*Chinese Pharmacopoeia Commission*

Professor She Qing, Chinese Pharmacopoeia Commission, Chongwen District, People's Republic of China

*Council of Europe, European Directorate for the Quality of Medicines and Health Care*

Mr J-M. Spieser and Dr K.H. Buchheit, OMCL Network and Health Care, Strasbourg, France

*Developing Country Vaccine Manufacturer's Network*

Dr S. Jadhav, Serum Institute of India Ltd, Pune, India

---

<sup>1</sup> The decisions of the Committee were taken in closed session with only members of the Committee present. Each Committee member had completed a declaration of interests form prior to the meeting. These were assessed by the WHO Secretariat and no declared interests were considered to be a conflict for full participation in the meeting

*European Medicines Agency*

Mr P. Richardson, Quality of Medicines Sector, London, UK

*European Generic Medicines Association*

Dr Martin Schiestl, Sandoz GmbH, Kundl, Tirol, Austria

*International Association of Biologicals*

Dr A. Eshkol, La Rippe, Switzerland

*International Federation of Clinical Chemistry and Laboratory Medicine*

Professor J-C. Forest, Centre Hospitalier Universitaire de Québec, Quebec, Canada

*International Federation of Pharmaceutical Manufacturers Associations*

Dr Irmgard Andresen, CSL Behring, Bern, Switzerland

Dr Michel Duchêne, GSK Biologicals, Wavre, Belgium

Andrew Fox, Global Regulatory Affairs & Safety, Thousand Oaks, CA, USA

Dr Jacques Mascaro, Global Regulatory Affairs, Elan Pharma International Ltd, Dublin, Ireland

Dr Inger Mollerup, Novo Nordisk A/S, Bagsværd, Denmark

Dr Alain Sabouraud, Sanofi Pasteur, Marcy l'Etoile, France

*International Organization for Standardization*

Mr T. Hancox, Geneva, Switzerland

*International Society of Blood Transfusion*

Dr E. Seifried, Blood Transfusion Centre of the German Red Cross, Institute of Transfusion Medicine und Immunohaematology, Frankfurt/Main, Germany

*International Society on Thrombosis and Haemostasis*

Professor K. Mertens, Sanguin Blood Supply Foundation, Amsterdam, The Netherlands

*Plasma Protein Therapeutics Association*

Dr Ilka von Hoegen, Quality and Safety, PPTA Europe

*United States Pharmacopeia*

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>